Teresa Scipioni

Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey

Michele Reni, M. Reni, E Giommoni, F C Bergamo et autres

BACKGROUND: Information about the adherence to scientific societies guidelines in the 'real-world' therapeutic management of oncological patients are lacking. This multicenter, prospective survey was aimed to improve the knowledge relative to 2017-2018 recommendations of the Italian Association of Medical Oncology (AIOM). PATIENTS …

it (code pays fourni par la source)

The VES-13 and G-8 tools as predictors of toxicity associated with aromatase inhibitors in the adjuvant treatment of breast cancer in elderly patients

Azzurra Irelli, Maria Maddalena Sirufo, Teresa Scipioni, Federica Aielli et autres

Background: Adjuvant hormone treatment of postmenopausal breast cancer is mainly based on aromatase inhibitors. Adverse events associated with such class of drugs are particularly severe in elderly patients. Therefore, we investigated the possibility of ab initio predict which elderly patients could encounter …

it (code pays fourni par la source)

Breast cancer patients receiving denosumab during adjuvant aromatase inhibitors treatment: who are the "inadequate responders" patients to denosumab?

Azzurra Irelli, Maria Maddalena Sirufo, Teresa Scipioni, Francesca De Pietro et autres

PURPOSE: Adjuvant hormone therapy with aromatase inhibitors (AIs) through the induction of tissue hypo-estrogenism induces an increase in osteoclast activity and inhibition of osteoblast activity through the production of RANKL. This is a relevant cause of comorbility in women affected by breast …

it (code pays fourni par la source)

The VES-13 and G-8 tools as predictors of toxicity associated with aromatase inhibitors in the adjuvant treatment of breast cancer in elderly patients: A single-center study

Azzurra Irelli, Teresa Scipioni, Federica Aielli, Francesco Martella et autres

Background: Adjuvant hormone treatment of postmenopausal breast cancer is mainly based on aromatase inhibitors. Adverse events associated with such class of drugs are particularly severe in elderly patients. Therefore, we investigated the possibility of ab initio predict which elderly patients could encounter …

it (code pays fourni par la source)

Denosumab in breast cancer patients receiving aromatase inhibitors: A single-center observational study of effectiveness in adjuvant setting

Massimo De Martinis, Azzurra Irelli, Teresa Scipioni, Amedeo Pancotti et autres

it (code pays fourni par la source)

Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain

Sebastiano Mercadante, Augusto Tommaso Caraceni, Francesco Masedu, Teresa Scipioni et autres

BACKGROUND: This study aimed to assess the characteristics of breakthrough cancer pain (BTcP) in patients receiving low doses of opioids for background pain in comparison with patients receiving at least 60 mg of oral morphine equivalents (OME). MATERIALS AND METHODS: Patients with …

us, it (code pays fourni par la source)

mTOR Links Tumor Immunity and Bone Metabolism: What are the Clinical Implications?

Azzurra Irelli, Maria Maddalena Sirufo, Teresa Scipioni, Francesca De Pietro et autres

Phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) plays a crucial role in the control of cellular growth, proliferation, survival, metabolism, angiogenesis, transcription, and translation. In most human cancers, alterations to this pathway are common and cause activation of other …

it (code pays fourni par la source)

The DOC combination in advanced gastric cancer: Preliminary data of a phase II study.

Amedeo Pancotti, Alessandra Santomaggio, G. Cianci, Teresa Scipioni et autres

104 Background: We describe activity of first line chemotherapy in advanced gastric carcinoma with docetaxel (DTX), oxaliplatin (OHP) and capecitabine (CAP). Methods: Patients (pts) were enrolled in the phase II study, if they had the main subsequent criteria: histologically confirmed diagnosis of …

Alpha-melanocyte-stimulating hormone antagonizes the inhibitory effect of corticotropin-releasing hormone on luteinizing hormone secretion during the luteal phase in normal women.

Paolo Piero Limone, Teresa Scipioni, P Calvelli, E.E. Scaglione et autres

CRH inhibits the secretion of gonadotropins by activating endogenous opioids, whereas alpha MSH, which displays various behavioral and neuroendocrine effects contrary to those of the opioids, stimulates their release. To evaluate the possible interaction of CRH and alpha MSH, eight women in …

it (code pays fourni par la source)

Preliminary Results of an Investigation on the Possible Interaction of α‐MSH and CRH in the Regulation of Gonadotropin Secretion

Paolo Piero Limone, Teresa Scipioni, P Calvelli, E.E. Scaglione et autres

it (code pays fourni par la source)